Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 5/2011

01-05-2011 | Original Article

Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity

Authors: Michele Basso, Anna Modoni, Daniele Spada, Alessandra Cassano, Giovanni Schinzari, Mauro Lo Monaco, Davide Quaranta, Pietro Attilio Tonali, Carlo Barone

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2011

Login to get access

Abstract

Purpose

There is no agreement on which channel is involved in oxaliplatin neurotoxicity, most investigators favouring voltage-gated sodium channels. However, the small conductance Ca++ activated K+ channels, encoded by the SK1–3 genes, are also involved in membrane excitability, playing a role in after-hyperpolarization at the motor nerve terminal. As the SK3 gene is characterized in Caucasians by a highly polymorphic CAG motif within the exon 1, we hypothesize that SK3 gene polymorphism may influence the development of acute nerve hyperexcitability in oxaliplatin-treated patients.

Methods

Patients eligible for an oxaliplatin-containing regimen were enrolled. Detailed neurological examination, nerve conduction studies and needle electromyography were performed before and after oxaliplatin administration. DNA was extracted by polymerase chain reaction, and each allele was isolated and sequenced.

Results

We evaluated 40 patients. After oxaliplatin administration, 28 patients developed symptoms of neurotoxicity, which were severe in 11. Patients were divided into three groups according to neurophysiological data: G0 (normal peripheral nerve excitability [PNE]), 16 patients; G1 (mild PNE), 15 patients; G2 (severe PNE), 9 patients. Genetic analysis showed different alleles ranging from 13 to 23 CAG repeats. Patients carrying alleles containing 13–15 CAG repeats experienced a significantly higher incidence of severe nerve hyperexcitability (chi-square 48.6; df 16; P = 0.0001).

Conclusion

The results suggest that OXA-neurotoxicity may be related to distribution of the polymorphic CAG motif of the SK3 gene, which might modulate nerve after-hyperpolarization. The 13–14 CAG repeat allele could mark patients susceptible to acute OXA neurotoxicity.
Literature
1.
go back to reference Culy CR, Clemett D, Wiseman LR (2000) Oxaliplatin: a review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60:895–924PubMedCrossRef Culy CR, Clemett D, Wiseman LR (2000) Oxaliplatin: a review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60:895–924PubMedCrossRef
2.
go back to reference de Gramont A, Figer A, Seymour H, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMed de Gramont A, Figer A, Seymour H, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMed
3.
go back to reference Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pilot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30PubMedCrossRef Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pilot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30PubMedCrossRef
4.
go back to reference Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29:21–33PubMedCrossRef Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29:21–33PubMedCrossRef
5.
go back to reference Cassidy J, Misset JL (2002) Oxaliplatin-related side-effects: characteristics and management. Semin Oncol 29:11–20PubMedCrossRef Cassidy J, Misset JL (2002) Oxaliplatin-related side-effects: characteristics and management. Semin Oncol 29:11–20PubMedCrossRef
6.
go back to reference Screnci D, McKeage M (1999) Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorg Biochem 77:105–110PubMedCrossRef Screnci D, McKeage M (1999) Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorg Biochem 77:105–110PubMedCrossRef
7.
go back to reference Wilson RH, Lehky T, Rebecca RT, Quinn MG, Floeter MK, Grem JL (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767–1774PubMedCrossRef Wilson RH, Lehky T, Rebecca RT, Quinn MG, Floeter MK, Grem JL (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767–1774PubMedCrossRef
8.
go back to reference Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29:387–392PubMedCrossRef Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29:387–392PubMedCrossRef
9.
go back to reference Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR (2002) Phenotypic variants of autoimmune perypheral nerve hyperexcitability. Brain 125:1887–1895PubMedCrossRef Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR (2002) Phenotypic variants of autoimmune perypheral nerve hyperexcitability. Brain 125:1887–1895PubMedCrossRef
10.
go back to reference Hart IK, Waters C, Vincent A, Newland C, Beeson D, Pongs O, Morris C, Newsom-Davis J (1997) Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 41:238–246PubMedCrossRef Hart IK, Waters C, Vincent A, Newland C, Beeson D, Pongs O, Morris C, Newsom-Davis J (1997) Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 41:238–246PubMedCrossRef
11.
go back to reference Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C (2000) The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406:25–32PubMedCrossRef Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C (2000) The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406:25–32PubMedCrossRef
12.
go back to reference Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A (2005) Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. British J Pharmacol 146:1027–1039CrossRef Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A (2005) Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. British J Pharmacol 146:1027–1039CrossRef
13.
go back to reference Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Phelate M, Gamelin E (2001) A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85:2293–2297PubMed Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Phelate M, Gamelin E (2001) A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85:2293–2297PubMed
14.
go back to reference Basso M, Cassano A, Modoni A, Spada D, Trigila N, Quirino M, Schinzari G, Barone C (2008) A reversibile coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance. Eur J Clin Pharmacol 64:739–741PubMedCrossRef Basso M, Cassano A, Modoni A, Spada D, Trigila N, Quirino M, Schinzari G, Barone C (2008) A reversibile coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance. Eur J Clin Pharmacol 64:739–741PubMedCrossRef
15.
go back to reference Kimura T, Takahashi MP, Fujimura H, Sakoda S (2003) Expression and distribution of a small-conductance calcium-activated potassium channel (SK3) protein in skeletal muscles from myotonic muscular dystrophy patients and congenital myotonic mice. Neurosci Lett 347:191–195PubMedCrossRef Kimura T, Takahashi MP, Fujimura H, Sakoda S (2003) Expression and distribution of a small-conductance calcium-activated potassium channel (SK3) protein in skeletal muscles from myotonic muscular dystrophy patients and congenital myotonic mice. Neurosci Lett 347:191–195PubMedCrossRef
16.
go back to reference Wittekindt O, Jauch A, Burgert E, Scharer L, Holtgreve-Grez H, Yvert G, Imbert G, Zimmer J, Hoehe MR, Macher JP, Chiaroni P, van Calker D, Crocq MA, Morris-Rosendahl DJ (1998) The human small conductance calcium-regulated potassium channel gene (hSKCa3) contains two CAG repeats in exon 1, is on chromosome 1q21.3 and shows a possible association with schizophrenia. Neurogenetics 1:259–265PubMedCrossRef Wittekindt O, Jauch A, Burgert E, Scharer L, Holtgreve-Grez H, Yvert G, Imbert G, Zimmer J, Hoehe MR, Macher JP, Chiaroni P, van Calker D, Crocq MA, Morris-Rosendahl DJ (1998) The human small conductance calcium-regulated potassium channel gene (hSKCa3) contains two CAG repeats in exon 1, is on chromosome 1q21.3 and shows a possible association with schizophrenia. Neurogenetics 1:259–265PubMedCrossRef
17.
go back to reference Chandy KG, Fantino E, Wittekindt O, Kalman K, Tong LL, Ho TH, Gutman GA, Crocq MA, Ganguli R, Nimgaonkar V, Morris-Rosedahl DJ, Gargus JJ (1998) Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate gene for schizophrenia and bipolar disorder. Mol Psychiatry 3:32–37PubMedCrossRef Chandy KG, Fantino E, Wittekindt O, Kalman K, Tong LL, Ho TH, Gutman GA, Crocq MA, Ganguli R, Nimgaonkar V, Morris-Rosedahl DJ, Gargus JJ (1998) Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate gene for schizophrenia and bipolar disorder. Mol Psychiatry 3:32–37PubMedCrossRef
18.
go back to reference Frei E, Spindler I, Grissmer S, Jager H (2006) Interactions of N-terminal and C-terminal parts of the small conductance Ca2+ activated K+ channel, hSK3. Cell Physiol Biochem 18:165–176PubMedCrossRef Frei E, Spindler I, Grissmer S, Jager H (2006) Interactions of N-terminal and C-terminal parts of the small conductance Ca2+ activated K+ channel, hSK3. Cell Physiol Biochem 18:165–176PubMedCrossRef
19.
go back to reference Miller SA, Dykes DD, Plensky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16:1215PubMedCrossRef Miller SA, Dykes DD, Plensky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16:1215PubMedCrossRef
20.
go back to reference Austin CP, Holder DJ, Ma L, Mixson LA, Caskey CT (1999) Mapping of hKCa3 to chromosome 1q21 and investigation of linkage of CAG repeat polymorphism to schizophrenia. Mol Psychiatry 4:261–266PubMedCrossRef Austin CP, Holder DJ, Ma L, Mixson LA, Caskey CT (1999) Mapping of hKCa3 to chromosome 1q21 and investigation of linkage of CAG repeat polymorphism to schizophrenia. Mol Psychiatry 4:261–266PubMedCrossRef
21.
go back to reference Grothey A, Hart LL, Rowland KM, Ansari RH, Alberts SR, Chowhan NM, Shpilsky A, Hochster HS (2008) Intermittent oxaliplatin (oxali) administration and time-to-treatment failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial. J Clin Oncol 26:(abstract 4010) Grothey A, Hart LL, Rowland KM, Ansari RH, Alberts SR, Chowhan NM, Shpilsky A, Hochster HS (2008) Intermittent oxaliplatin (oxali) administration and time-to-treatment failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial. J Clin Oncol 26:(abstract 4010)
22.
go back to reference McIntyre CC, Richardson AG, Grill WM (2002) Modeling the excitability of mammalian nerve fibers: influence of afterpotentials on recovery cycle. J Neurophysiol 87:995–1006PubMed McIntyre CC, Richardson AG, Grill WM (2002) Modeling the excitability of mammalian nerve fibers: influence of afterpotentials on recovery cycle. J Neurophysiol 87:995–1006PubMed
23.
go back to reference Wittekindt OH, Visan V, Tomita H, Imtiaz F, Gargus JJ, Lehmann-Horn F, Grissmer S, Morris-Rosendahl DJ (2004) An apamin- and scyllatoxin-insensitive isoform of the human SK3 channel. Mol Pharmacol 65:788–801PubMedCrossRef Wittekindt OH, Visan V, Tomita H, Imtiaz F, Gargus JJ, Lehmann-Horn F, Grissmer S, Morris-Rosendahl DJ (2004) An apamin- and scyllatoxin-insensitive isoform of the human SK3 channel. Mol Pharmacol 65:788–801PubMedCrossRef
24.
go back to reference Tomimitsu H, Kimiyoshi A, Nagado T, Watanabe O, Otsuka R, Kurono A, Sonoda Y, Osame M, Kameyama M (2004) Mechanism of action of voltage-gated K+ channels antibodies in acquired neuromyotonia. Ann Neurol 56:440–444PubMedCrossRef Tomimitsu H, Kimiyoshi A, Nagado T, Watanabe O, Otsuka R, Kurono A, Sonoda Y, Osame M, Kameyama M (2004) Mechanism of action of voltage-gated K+ channels antibodies in acquired neuromyotonia. Ann Neurol 56:440–444PubMedCrossRef
25.
go back to reference Mark Duffy S, Berger P, Cruse G, Yang W, Bolton SJ, Bradding P (2004) The K+ channels iKCA1 potentiates Ca2+ influx and degranulation in human lung mast cells. J Allergy Clin Immunol 114:66–72PubMedCrossRef Mark Duffy S, Berger P, Cruse G, Yang W, Bolton SJ, Bradding P (2004) The K+ channels iKCA1 potentiates Ca2+ influx and degranulation in human lung mast cells. J Allergy Clin Immunol 114:66–72PubMedCrossRef
26.
go back to reference Maindrault-Goebel F, Andrè T, Tournigand C, Louvet C, Perez-Staub N, Zaghib N, de Gramont A (2005) Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patinets. Eur J Cancer 41:2262–2267. [Epub 2005 Sep 9] Maindrault-Goebel F, Andrè T, Tournigand C, Louvet C, Perez-Staub N, Zaghib N, de Gramont A (2005) Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patinets. Eur J Cancer 41:2262–2267. [Epub 2005 Sep 9]
27.
go back to reference Siu SW, Chan RT, Au GK (2006) Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 17:259–261. [Epub 2005 Nov 9] Siu SW, Chan RT, Au GK (2006) Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 17:259–261. [Epub 2005 Nov 9]
Metadata
Title
Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity
Authors
Michele Basso
Anna Modoni
Daniele Spada
Alessandra Cassano
Giovanni Schinzari
Mauro Lo Monaco
Davide Quaranta
Pietro Attilio Tonali
Carlo Barone
Publication date
01-05-2011
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-010-1466-y

Other articles of this Issue 5/2011

Cancer Chemotherapy and Pharmacology 5/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine